MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Washington University (WashU) in St. Louis, Missouri, USA. The agreement marks the next chapter in a nearly century-long partnership dedicated to advancing scientific research and innovation.
The expanded collaboration will support joint research initiatives, technology scouting, and research enablement, with an emphasis on fostering sustainable and socially responsible scientific progress. Together, MilliporeSigma and WashU aim to strengthen the talent pipeline, accelerate the transition from lab discoveries to clinical applications, and help eventually bring life-saving therapies to patients faster.
Through the partnership, MilliporeSigma will provide access to its broad portfolio of products, services, and technical expertise, helping researchers innovate more efficiently and effectively. The MoU also expands MilliporeSigma’s efforts to support early-stage innovation by engaging with startups and incubators, offering emerging ventures resources and services tailored to accelerate their growth.
WashU’s campus is located near MilliporeSigma’s network of production and R&D sites in St. Louis where the company employs nearly 2,300 people. Over the last five years, the company has invested more than $250 million in its St. Louis operations, further strengthening its regional footprint and advancing local scientific capabilities.
Image caption- WashU Chancellor Andrew D. Martin (L); and Jean-Charles Wirth, CEO MilliporeSigma (R)
